Compare Marriott International Inc (MAR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Repligen Corporation Common Stock — how do they compare? Marriott International Inc trades at $374.73 (market cap $96.96B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Marriott International Inc is far larger — about 8.6× Repligen Corporation Common Stock's market cap, and Marriott International Inc pays a 0.79% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Repligen Corporation Common Stock for 0 Days on average.
| MAR | RGEN | |
|---|---|---|
Market Cap | $96.96B | $11.31B |
Volume | 1,354,129 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $194.57 |
52-Week Low | $259.04 | $102.87 |
Typical Hold Time | 164 Days | 0 Days |
Enterprise Value | $114.27B | $11.20B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $371.50, up 0.6% today, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported revenue of $26.19B in 2025, with net income of $2.60B, though it missed Q4 2025 EPS estimates. Valuation ratios like P/E of 38.46 and P/S of 3.71 indicate a premium, while debt levels have risen to 58.83% of assets in 2025. Recent news highlights partnerships and dividend declarations, reinforcing its travel sector resilience.
The stock offers growth potential from sustained travel demand and strategic expansions, but faces risks from high leverage and economic sensitivity. Analysts are mostly neutral with a consensus price target of $388.93, suggesting modest upside. Investors should weigh solid profitability against valuation concerns and macroeconomic headwinds.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
